Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

meistermell May. 13 at 4:19 PM

$ESPR what competition is dingbat talking about, BA has zero competition besides the generics on 2040. All other lipid lowering drugs do not work.

1 · Reply

OldManLogan May. 13 at 2:50 PM

$ESPR This is sincerely my take as well. Many of the things that didn't make sense before only make sense once you assume that Sheldon and Ben made a concerted effort to tank the share price in order to get a lowball deal through. Frankly, while absolutely disgusting, it's impressive that they could tank the share price at the same time that ESPR got included in the guidelines in a major way... that's why they promised then backed off on profitability; why they said that Japan was killing it at first but then said 'don't expect too much from Japan'. That's why they bought Enbumyst after promising not to go out and buy companies. It was all an effort to create HUGE phantom premium so that a disgustingly low offer could succeed. I hope for the remaining longs that another bid shows up, but Sheldon and Ben and very incentivized to stop that from happening. Cheers to longs.

2 · Reply

wRsYUeX May. 13 at 1:26 PM

$ESPR

0 · Reply

biotech_sellout May. 13 at 1:18 PM

$ESPR AWESOME NEWS TODAY! IT SHOULD DEFINITELY POP THE STOCK TO $3.16!

0 · Reply

kemah May. 13 at 1:04 PM

$ESPR ARCHIMED take-private (May 1) — big bank analyst reactions: *2/5 top analysts commented & adjusted: • Dennis Ding (Jefferies): Downgraded Buy→Hold, PT to $3.28 (from $5). “Good outcome” but no upside left beyond $3.16 offer due to coming competition. • Kristen Kluska (Cantor): Downgraded to Neutral, PT $3.16. Deal “appears low” vs ~$1.5B peak sales potential. *Other 3 silent: Zemansky (BofA), Choi (GS), Fye (JPM). Stock ~$3.16 + CVR. Close Q3 expected. Why no auction process? Why this single covert PE deal? Shareholders deserve full transparency on the rushed process.

0 · Reply

refinedindividual May. 13 at 12:40 PM

$ESPR Where is the voting material for the 5/28 meeting? How can we not elect directors so this LOUSY merger dies

1 · Reply

TripleWitch May. 13 at 12:29 PM

$ESPR this company is being stolen by CRIMINALS…. 🗑️ 🔥 🗑️

0 · Reply

MrPeter May. 13 at 12:01 PM

$ESPR and now they are issuing press releases for a new study?

1 · Reply

Stock765 May. 13 at 11:33 AM

$ESPR Esperion accepted a low bowl offer and now you'r sitting in your small, dark boffer - don'r worry, be happy! Would Sheldon really want to sell the shares he earned for his life's work so cheaply? I seriously doubt it.

1 · Reply

Erve7 May. 13 at 10:58 AM

$ESPR Damn...What the Fuck is wrong with this stock. Are these guys going to announces their Q1 2026 results one day?

2 · Reply

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

2026-05-04T19:10:14.000Z - 8 days ago

Esperion downgraded to Hold from Buy at Needham

2026-05-01T19:26:03.000Z - 11 days ago

Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T18:06:50.000Z - 11 days ago

Esperion downgraded to Neutral from Overweight at Piper Sandler

2026-05-01T15:12:52.000Z - 12 days ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T12:46:24.000Z - 12 days ago

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

May 1, 2026, 7:37 AM EDT - 12 days ago

Archimed to take Esperion Therapeutics private in $1.1 billion deal

2026-05-01T11:17:53.000Z - 12 days ago

Esperion to be acquired by Archimed for $3.16 per share, one CVR

May 1, 2026, 7:00 AM EDT - 12 days ago

Esperion to be Acquired by ARCHIMED

Apr 23, 2026, 8:00 AM EDT - 20 days ago

Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 13, 2026, 9:30 AM EDT - 4 weeks ago

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-02T20:16:16.000Z - 5 weeks ago

Esperion, Athyrium Capital enter $50M royalty financing agreement

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:00 PM EDT - 5 weeks ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

2026-03-30T13:21:46.000Z - 6 weeks ago

Esperion showcases new data from CLEAR Outcomes trial

2026-03-16T10:51:45.000Z - 2 months ago

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

Mar 16, 2026, 6:30 AM EDT - 2 months ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

2026-03-13T09:36:20.000Z - 2 months ago

Esperion price target raised to $5 from $4 at Citizens

Mar 11, 2026, 8:25 AM EDT - 2 months ago

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:06:41.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 10, 2026

AVAV BNTX FNV GRPN KSS NIO ORCL

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025

2026-03-10T10:06:52.000Z - 2 months ago

Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:13.000Z - 2 months ago

Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

Mar 10, 2026, 6:00 AM EDT - 2 months ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 8:00 AM EST - 2 months ago

Esperion Therapeutics Transcript: M&A announcement

2026-03-03T11:05:38.000Z - 2 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics

Mar 3, 2026, 6:00 AM EST - 2 months ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 3 months ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

2026-02-17T13:16:28.000Z - 3 months ago

Esperion reaches settlement agreement with Alkem

Feb 17, 2026, 8:00 AM EST - 3 months ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 11, 2026, 4:30 PM EST - 3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 14, 2026, 5:15 PM EST - 4 months ago

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T00:25:16.000Z - 4 months ago

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

Jan 11, 2026, 6:00 PM EST - 4 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

2025-12-19T13:16:23.000Z - 5 months ago

Esperion’s bempedoic acid receives recommendation in 2025 ACC statement

Dec 3, 2025, 3:30 PM EST - 5 months ago

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 7:00 AM EST - 6 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 3:00 AM EST - 6 months ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 2:00 PM EST - 6 months ago

Esperion Therapeutics Transcript: KOL Event

Nov 6, 2025, 8:00 AM EST - 6 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 7, 2025, 9:29 PM EDT - 7 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 7 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 7 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 8 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 8, 2025, 2:00 PM EDT - 8 months ago

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:45 AM EDT - 9 months ago

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 10 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 11 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 9, 2025, 10:40 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:30 PM EDT - 1 year ago

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 5, 2024, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 11:30 AM EST - 1 year ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 1 year ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

meistermell May. 13 at 4:19 PM

$ESPR what competition is dingbat talking about, BA has zero competition besides the generics on 2040. All other lipid lowering drugs do not work.

1 · Reply

OldManLogan May. 13 at 2:50 PM

2 · Reply

wRsYUeX May. 13 at 1:26 PM

$ESPR

0 · Reply

biotech_sellout May. 13 at 1:18 PM

$ESPR AWESOME NEWS TODAY! IT SHOULD DEFINITELY POP THE STOCK TO $3.16!

0 · Reply

kemah May. 13 at 1:04 PM

0 · Reply

refinedindividual May. 13 at 12:40 PM

$ESPR Where is the voting material for the 5/28 meeting? How can we not elect directors so this LOUSY merger dies

1 · Reply

TripleWitch May. 13 at 12:29 PM

$ESPR this company is being stolen by CRIMINALS…. 🗑️ 🔥 🗑️

0 · Reply

MrPeter May. 13 at 12:01 PM

$ESPR and now they are issuing press releases for a new study?

1 · Reply

Stock765 May. 13 at 11:33 AM

1 · Reply

Erve7 May. 13 at 10:58 AM

$ESPR Damn...What the Fuck is wrong with this stock. Are these guys going to announces their Q1 2026 results one day?

2 · Reply

paivante69 May. 13 at 9:10 AM

$ESPR Exit Clause: Depending on the merger agreement (Merger Agreement), a hostile change of control or the inability to retain the board may give ARCHIMED the right to cancel the agreement or demand a termination fee (Separation Fee). 3. Nomination of Alternatives If activist shareholders (or institutional funds) manage to reject the current directors, they will attempt to nominate their own candidates for the board of directors. These new directors would have the mandate to: Cancel the current agreement with ARCHIMED. Open a new auction process to seek a higher counter-offer from another pharmaceutical company.

0 · Reply

paivante69 May. 13 at 9:09 AM

$ESPR If Esperion's directors are not re-elected at the Annual General Meeting on May 28, 2026, this will cause an immediate corporate impasse and directly affect the sale to ARCHIMED. The practical impacts are divided into three legal and financial scenarios: 1. Holdover Rule According to Delaware corporate law (where Esperion is registered) and the company's bylaws, current directors do not leave office immediately if they lose the election. They remain in office as "holdover directors" until their successors are duly elected and qualified. The board of directors does not become vacant overnight. 2. Direct Threat to the Merger with ARCHIMED The failure to be re-elected reflects a total shareholder revolt against the current management due to the price of $3.16 per share. This generates serious consequences for the business: Loss of Confidence: ARCHIMED may interpret the rejection as a sign that shareholders will reject the merger at the subsequent extraordinary general meeting.

1 · Reply

jn32 May. 13 at 8:22 AM

$ESPR Comparing it to other biotechs that announced being bought by a PE firm then got out bidded I’d say if you’re holding I’d hold for atleast 40 days from ESPRs announcement

0 · Reply

Eugen337 May. 13 at 6:01 AM

$ESPR Oh, don't worry, he's fine! He'll even take care of your health!

0 · Reply

meistermell May. 13 at 2:47 AM

$ESPR better than not investing in derisked biotechs is not to engage with the boiler room, mute them all, and buy the crap out of such as stock at sub 1 and sub 2, cant get any more derisked than that if you studied the drug and did your homework. Crooked mgmt can always cut your gains but the boiler room bashers is what's keeping many from making (more) money. Look through the financials, even back then, and tell me this wasn't a sure shot, even with the con artists at the helm. BA is a miracle drug

0 · Reply

perchedcats May. 13 at 2:29 AM

$ESPR sheldon and the BoD are dying to give this away to Archimed. they will enrich themselves handsomely - their payout for making sure ArchiMed lands the company. just look at the too-short go-shop window that basically cuts out Daiichi and Otsuka - japanese companies are slow / approving a BO and would take longer. that short go-shop window is another piece of evidence of the collusion between Sheldon the BoD and ArchiMed

0 · Reply

Gary9912 May. 13 at 1:32 AM

$ESPR Most of us made money here, just not as much as we had hoped for. I still truly believe we (the ones that continue to hold) have more money coming our way but if that is not the case and the story plays out like the animation below, I’ll chalk it up to a learning experience and never invest in another small biotech company ever again.💪🙏💰

1 · Reply

Gregg617 May. 13 at 1:01 AM

$ESPR ok last one fitting

0 · Reply

biotech_sellout May. 13 at 12:50 AM

$ESPR Can someone do a wellness check on Gregg?

1 · Reply

JasonZemanskyPhD May. 12 at 11:38 PM

$ESPR life Gregg life. Some time u need to let go things by yourself else you will be forced to.

1 · Reply

NEWBIGTECH May. 12 at 10:06 PM

$ESPR

0 · Reply

Enjoyycall May. 12 at 9:25 PM

$ESPR Someone else about to scrub their account I see. Un-used "work". They not like us.

0 · Reply

Market Cap	805.68M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	68.26
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	9,087,900
Avg Vol	12,174,937
Day's Range	N/A - N/A
Shares Out	257.41M
Stochastic %K	96%
Beta	0.91
Analysts	Hold
Price Target	$2.91